Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

12.23 -0.02 (-0.16%)

Delayed Quote Updated: 9:46 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

November 28, 2024

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

November 26, 2024

From Dr. Reddy's Laboratories, Inc.

Via Business Wire

Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17% ↗

November 05, 2024

Dr. Reddy's Q2 2025 report shows a revenue boost to $957 million, fueled by global generics. North American sales rose 17% year-over-year.

Via Benzinga

Dr. Reddy’s Q2 & H1FY25 Financial Results

November 05, 2024

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year

October 25, 2024

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month

October 14, 2024

From Dr. Reddy’s Laboratories Inc.

Via Business Wire

Market Alert: Dr. Reddy’s Labs Reports New Data for Aurigene CAR-T Phase 1, Gets Approvals for Phase 2 Trials Progression

October 09, 2024

Via AB Newswire

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma

October 08, 2024

From Aurigene Oncology Limited

Via Business Wire

Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries

October 02, 2024

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr. Reddy's Laboratories – Elliott Wave Technical Analysis ↗

September 20, 2024

Dr Reddy's Laboratories is progressing lower within a counter trend zigzag to terminate Minor Wave 4 Grey around 5600 levels.

Via Talk Markets

Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again? ↗

September 03, 2024

Dr. Reddy's Labs sees its Relative Strength Rating enter the 80-plus level.

Via Investor's Business Daily

Organon Stock Sees Relative Strength Rating Rise To 91 ↗

August 27, 2024

On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before.

Via Investor's Business Daily

Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal ↗

August 24, 2024

Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with...

Via Talk Markets

Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold ↗

August 20, 2024

On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier.

Via Investor's Business Daily

Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug

August 20, 2024

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar

July 29, 2024

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr. Reddy’s Q1FY25 Financial Results

July 27, 2024

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem

July 10, 2024

Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024

Via MarketBeat

Should Quality-Oriented Investors Explore DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)? ↗

July 01, 2024

DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) can be considered a quality stock. Here's why.

Via Chartmill

Dr. Reddy's Labs Stock Sees Improved Technical Strength ↗

June 28, 2024

On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76.

Via Investor's Business Daily

Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M ↗

June 26, 2024

Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for £500 million ($632 million). This strategic move allows Haleon to focus on growth...

Via Benzinga

Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities

June 03, 2024

From Aurigene Pharmaceutical Services Ltd.

Via Business Wire

Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business

June 26, 2024

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High. ↗

June 03, 2024

Exit polls forecast a landslide win and third consecutive term for Prime Minister Narendra Modi in India's general elections.

Via Investor's Business Daily

Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America

May 28, 2024

From Dr. Reddy's Laboratories Ltd.

Via Business Wire

Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK

May 21, 2024

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK

May 21, 2024

From Alvotech

Via GlobeNewswire

RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024 ↗

May 07, 2024

RDY stock results show that Dr Reddy's Laboratories beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.

Via InvestorPlace

Dr. Reddy’s Q4 & Full Year FY24 Financial Results

May 07, 2024

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.

May 03, 2024

From Dr. Reddy's Laboratories Ltd.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.